Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Private Equity Strategies

Data Snapshot: Chinese Private Equity Gets More Open

Tuesday, January 22, 2013

By: Bailey McCann, Private Equity Strategies

As we noted in Regs Watch, China has opted to leave private equity and venture capital funds out of the regulatory fray until governing bodies can decide how best to monitor them. Near the end of 2012, Shanghai also quietly launched a new pilot program - RMB Qualified Foreign Limited Partner (RQFLP), to permit qualified foreign fund managers and asset management companies to raise offshore RMB from offshore investors to invest in RMB private equity funds set up in Shanghai. According to attorneys for global law firm Mayer Brown, participants in the RQFLP program are intended to include both well-established foreign fund managers with the fundraising capacity for offshore RMB and the Hong Kong subsidiaries of Chinese asset management companies and brokerage firms.

Factsheet - What You Need To Know:

  • The number of limited partners in the Chinese venture capital and private equity industry totaled 7,511 by the end of 2012.
  • 6,323 of the limited partnerships, or 84.2%, were Chinese, while 1,134 were foreign limited partnerships.
  • Of the 9,000 private equity deals and venture capital deals completed in China since 2001, $100bn, much from US funds still remains invested in the region.
  • 2,200 deals completed before 2008 still have $22bn in funds tied up in slow exits, as firms have a hard time since the halt in Chinese IPOs.

Sources: China First Capital, Zero2IPO Group

 
This article was published in Opalesque's Private Equity Strategies our monthly research update on the global private equity landscape including all sectors and market caps.
Private Equity Strategies
Private Equity Strategies
Private Equity Strategies


Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for